CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

This publication has 24 references indexed in Scilit:

• Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting
  New England Journal of Medicine, 2012
• Genetic determinants of platelet response to clopidogrel
  Journal of Thrombosis and Thrombolysis, 2011
• Impact of Bleeding on Mortality After Percutaneous Coronary Intervention
  JACC: Cardiovascular Interventions, 2011
• Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI
  JAMA, 2010
• Cytochrome P-450 Polymorphisms and Response to Clopidogrel
  New England Journal of Medicine, 2009
• Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
  The Lancet, 2009
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
  Journal of Thrombosis and Haemostasis, 2007
• Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 2007
• Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
  Circulation, 2006
• Labor and Health Status in Economic Evaluation of Health Care: The Health and Labor Questionnaire
  International Journal of Technology Assessment in Health Care, 1996